Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RARA
REST API REST API
Homo sapiens
RARA is differentially expressed in 321 experiments: 147 organism parts: lung, hypothalamus, ... (145 more);, 227 disease states: normal, glioblastoma, ... (225 more);, 103 cell types 388 cell lines 50 compound treatments and 82 other conditions.
Synonyms NR1B1, RAR
Orthologs Rara (Mus musculus)   raraa (Danio rerio)   rarab (Danio rerio)   F1MWQ3_BOVIN (Bos taurus)   F6VND6_CIOIN (Ciona intestinalis)   Rara (Rattus norvegicus)   rara (Xenopus laevis)   RARA_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, negative regulation of translational initiation, cytoplasm, nuclear chromatin, apoptotic cell clearance, ligand-dependent nuclear receptor activity, transcription, DNA-dependent, positive regulation of cell proliferation, positive regulation of gene expression, transcription corepressor activity, metal ion binding, spermatogenesis, receptor binding, protein domain specific binding, multicellular organism growth, sequence-specific DNA binding, protein kinase A binding, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, protein heterodimerization activity, dendrite, chromatin DNA binding, germ cell development, receptor activity, positive regulation of cell cycle, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, cell surface, negative regulation of cell differentiation, negative regulation of gene expression, enzyme binding, steroid hormone receptor activity, signal transduction, positive regulation of transcription, DNA-dependent, zinc ion binding, neuronal cell body, retinoic acid binding, chondroblast differentiation, cellular response to retinoic acid, positive regulation of interleukin-4 production, retinoic acid receptor activity, steroid hormone mediated signaling pathway, estrogen receptor signaling pathway, growth plate cartilage development, negative regulation of granulocyte differentiation, intracellular receptor mediated signaling pathway, gene expression, cellular response to estrogen stimulus, negative regulation of interferon-gamma production, response to retinoic acid, regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor, response to estradiol stimulus, negative regulation of tumor necrosis factor production, ventricular cardiac muscle cell differentiation, regulation of granulocyte differentiation, protein kinase B binding, positive regulation of binding, cellular response to lipopolysaccharide, ureteric bud development, retinoic acid receptor signaling pathway, negative regulation of cartilage development, positive regulation of T-helper 2 cell differentiation, sequence-specific DNA binding transcription factor activity, protein phosphorylation, positive regulation of interleukin-13 production, positive regulation of interleukin-5 production, retinoic acid-responsive element binding, transcription regulatory region DNA binding, Sertoli cell fate commitment
InterPro Term Nucl_hrmn_rcpt_lig-bd_core, ThyrH_rcpt, Str_hrmn_rcpt, Znf_hrmn_rcpt, Nuc_orph_rcpt, Retinoic_acid_rcpt, Retinoid-X_rcpt
UniProt Accession A8MUP8, Q6I9R7, P10276, C9JS86, B8Y636, F1D8N9, F8W8A4
Gene-Disease Assocation ACUTE PROMYELOCYTIC LEUKEMIA; APL
Search EB-eye ENSG00000131759
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (39 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-GEOD-18005, E-MTAB-37, E-GEOD-2509
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
MDA468
2
E-MTAB-62, E-MEXP-440
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-GEOD-5258, E-MEXP-2034
BT474
1
2
E-MTAB-37, E-MTAB-62, E-MEXP-440
382 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (54 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD8+ T cell
2
E-GEOD-6740, E-GEOD-19069
embryonic stem cell
1
E-GEOD-26672
spheroid recovery
1
E-GEOD-4219
leydig cell
1
E-MTAB-25
naive T cell
1
E-GEOD-1460
97 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-12254, ... (68 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
melanoma
2
E-MTAB-62, E-MTAB-37
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-2379
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
221 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-4748, E-TABM-868
control
2
E-GEOD-3284, E-GEOD-4006
none
5
6
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-TABM-868, E-GEOD-5099, ... (11 experiments)
4,5-dianilinophthalimide
2
1
E-GEOD-5258
selenium
1
E-MEXP-1327
glutamine
1
E-MEXP-941
44 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
83
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22541, E-GEOD-2509, E-GEOD-22148, ... (7 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-17476, E-GEOD-2466, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-16194, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-MEXP-2069, E-TABM-26, ... (39 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.506 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM